ProMIS Neurosciences Inc PMN

Dream.

[Alex1726]

Contrary To Dr. Cashman and Goldstein , Giovinazzo is not a dreamer , he knows that if you don't do any clinical trial , you can't reach any agreement with a partner , if you always run out of cash and if you shoot in all diretions : Covid , AD vaccine , then you're going nowhere especially not on Nasdaq.

Keep on dreaming.

[Gbathat]

PMN310 is still the dream, as it was when Giovinazzo came on board. Cracking that market is a huge lift, and doing R&D in some of these other areas while the PMN310 business plan matures is time well spent.  This company has a capability, not just a one-off product.  PMN310 clinical entry has been admittedly behind schedule. But the bottom line is that aducanumab and BAN2401 leave

[farmerjane]

Your bottom paragraph on Biogen, but why not some other Pharma when Biogen has moved the goal post further than any body else!!

[Gbathat]

I also have wondered the same and posted that here previously.  It is unclear to me.  All I know from the PRs is that PMN 310 appears to be tied to aducanumab's progression.  I also see that PMN310 has been acknowledged as next-gen in a review paper published by others in the industry.  I am trying to connect the dots, just like the rest of us on this board.

[G1945V]

PMN needs will know that the beta-amyloid hypothesis is not a dead issue. FDA approval of aducanumab will set that straight by approving aducanumab. If that is the case, Biogen will go to the market.    That will open it up for PMN. PMN will partner up with a BP ( competitor to Biogen)  to fund the clinical trials and move forward from that point.    jmo

[retiredcop]

It's not PMN310 that's attached to aducanumabs progression ...it's the amyloid science pertaining to alzhiemers...there has been constant failures and setbacks for the amyloid approach and many dont want to flog a dead horse....that's what everyone is waiting to see ....the FDA  endorsement is apparently the best validation that can happen at this time...and get investors t